Frentizole therapy of active systemic lupus erythematosus.

Abstract

Frentizole is a benzimidazoleurea that has immunosuppressive properties in mice. Eleven steroid-treated patients with active systemic lupus erythematosus received frentizole (150-350 mg/day) in combination with stable or decreasing doses of prednisone in an open label trial. Nine patients completed at least one 21- to 75-day course of therapy with this drug. Clinical parameters of disease improved in 8 of these 9 patients. Mean DNA binding decreased by 28%, mean CH50 increased by 20%, and mean absolute lymphocyte and T cell counts decreased by 25-26%. Granulocytopenia was not observed. Three patients developed reversible hepatic toxicity. Clinical and serologic improvement was noted in 3 patients who accepted a second 90-day course of frentizole therapy.

• Authors: D R Kay, T V Valentine, S E Walker, M H Valentine, G G Bole
• Journal: Arthritis and rheumatism (Arthritis Rheum) Vol. 23 Issue 12 Pg. 1381-7 (Dec 1980) ISSN: 0004-3591 [Print] United States
• PMID: 7006613 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Benzothiazoles
• Immunosuppressive Agents
• Phenylurea Compounds
• Thiazoles
• frentizole
• Prednisone

Topics

• Adolescent
• Adult
• Benzothiazoles
• Clinical Trials as Topic
• Drug Administration Schedule
• Drug Therapy, Combination
• Female
• Follow-Up Studies
• Humans
• Immunosuppressive Agents
• Lupus Erythematosus, Systemic (drug therapy, immunology)
• Male
• Middle Aged
• Phenylurea Compounds (administration & dosage, therapeutic use)
• Prednisone (administration & dosage)
• Thiazoles (administration & dosage, therapeutic use)
• Time Factors